Evaxion Biotech Revenue and Competitors
Estimated Revenue & Valuation
- Evaxion Biotech's estimated annual revenue is currently $13.8M per year.
- Evaxion Biotech's estimated revenue per employee is $155,000
Employee Data
- Evaxion Biotech has 89 Employees.
- Evaxion Biotech grew their employee count by -7% last year.
Evaxion Biotech's People
| Name | Title | Email/Phone |
|---|
Evaxion Biotech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Evaxion Biotech?
Since 2008, Evaxion Biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using Artificial Intelligence, with the mission to solve some of the world's most significant challenges to human health. Evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, PIONEER and EDEN. Using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. EDEN enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while PIONEER has been constructed to identify the epitopes of mutated proteins that will fire up the body's natural immune responses to them. To learn more about Evaxion, please visit http://www.evaxion-biotech.ai
keywords:N/A
N/A
Total Funding
89
Number of Employees
$13.8M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Evaxion Biotech News
Comparatively, Evaxion Biotech A/S has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500. Profitability.
A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Renaissance Technologies LLC purchased a new stake in shares of Evaxion...
COPENHAGEN, Denmark, April 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (Evaxion or the Company), a clinical-stage...